Somewhat Critical Media Coverage Somewhat Unlikely to Impact Natus Medical (BABY) Share Price
News coverage about Natus Medical (NASDAQ:BABY) has trended somewhat negative recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Natus Medical earned a daily sentiment score of -0.03 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 46.0606434709178 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Newborn Screening Global Market 2018: Key Players – Perkinelmer, Inc., Natus Medical Incorporated, Agilent Technologies Inc. (industrytoday.co.uk)
- As Entergy (ETR) Share Value Rose, Cognios Capital Cut Its Position; Beddow Capital Management Position in Natus … – Hill Country Times (hillcountrytimes.com)
- Why Investors remained confident on Natus Medical Incorporated (BABY), Tronox Limited (TROX)? – Newburgh Gazette (newburghgazette.com)
- Natus Medical (BABY) Downgraded by Zacks Investment Research (americanbankingnews.com)
- The Global Newborn Screening Market is accounted from $599.77 million in 2016 to reach $1395.65 million by 2023 with a CAGR of 12.7% (markets.businessinsider.com)
Shares of Natus Medical (NASDAQ BABY) opened at $28.95 on Tuesday. The company has a quick ratio of 3.36, a current ratio of 4.21 and a debt-to-equity ratio of 0.36. Natus Medical has a 52 week low of $28.40 and a 52 week high of $43.60. The stock has a market cap of $901.91, a price-to-earnings ratio of -321.63 and a beta of 0.84.
Several research firms have recently commented on BABY. Zacks Investment Research cut shares of Natus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. BidaskClub lowered shares of Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 6th. Finally, William Blair lowered shares of Natus Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $46.50.
In other Natus Medical news, Director William M. Moore sold 5,000 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $41.01, for a total transaction of $205,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Dong Chune Christopher Chung sold 12,642 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $42.91, for a total transaction of $542,468.22. Following the transaction, the vice president now directly owns 141,414 shares of the company’s stock, valued at approximately $6,068,074.74. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.